Impact of Tumor Location on Patient Outcomes in Small Bowel Cancers.

Autor: Yu IS; BC Cancer, Vancouver, British Columbia, Canada., Al-Hashami Z; BC Cancer, Vancouver, British Columbia, Canada., Chapani P; University of British Columbia, Vancouver, British Columbia, Canada., Speers C; Gastrointestinal Cancer Outcomes Unit, BC Cancer, Vancouver, British Columbia, Canada., Davies JM; BC Cancer, Vancouver, British Columbia, Canada; University of British Columbia, Vancouver, British Columbia, Canada., Lim HJ; BC Cancer, Vancouver, British Columbia, Canada; University of British Columbia, Vancouver, British Columbia, Canada., Renouf DJ; BC Cancer, Vancouver, British Columbia, Canada; University of British Columbia, Vancouver, British Columbia, Canada., Gill S; BC Cancer, Vancouver, British Columbia, Canada; University of British Columbia, Vancouver, British Columbia, Canada., Stuart HC; BC Cancer, Vancouver, British Columbia, Canada; University of British Columbia, Vancouver, British Columbia, Canada., Loree JM; BC Cancer, Vancouver, British Columbia, Canada; University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: Jonathan.Loree@bccancer.bc.ca.
Jazyk: angličtina
Zdroj: Clinical colorectal cancer [Clin Colorectal Cancer] 2022 Jun; Vol. 21 (2), pp. 107-113. Date of Electronic Publication: 2021 Dec 01.
DOI: 10.1016/j.clcc.2021.11.006
Abstrakt: Background: Small bowel cancers are rare gastrointestinal malignancies and tumor location impact on outcomes is unclear.
Material and Methods: A retrospective review was performed on stage I to IV small bowel cancer cases from 2000 to 2017 in British Columbia, Canada. Baseline patient characteristics, disease-free survival (DFS) and overall survival (OS) were evaluated by tumor location and systemic therapy use patterns were summarized.
Results: Of 340 patients included, primary tumor distribution was: duodenum (51.2%), ileum (19.1%), jejunum (18.5%), and unspecified (11.2%). Median DFS for stage I to III disease was 37.7, 49.1, and 26.7 months for duodenal, jejunal, and ileal tumors (P = .018). Median OS was 9.6, 35.2, and 20.1 months for duodenal, jejunal, and ileal tumors (P < .0001). Compared to duodenal primaries, both jejunal and ileal tumors were associated with significantly improved OS (HR 0.43, P < .001 for jejunal; HR 0.71, P = .035 for ileal). Adjuvant therapy was given to 21.6% of stage II and 50.6% of stage III cancers. Among patients with metastatic disease, median OS was 4.2, 11.4, and 6.9 months for duodenal, jejunal, and ileal tumors (P = .0019). Jejunal tumors had the best prognosis (HR 0.48, P = .001 vs. duodenum).
Conclusion: Survival differences exist when small bowel cancers were assessed by tumor location, and jejunal tumors portended better prognosis overall.
(Copyright © 2021. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: